


We claim:

1. A compound of the formula:




5

wherein X is selected from the group comprising O and S;
wherein A_1 and A_2 are individually selected from the
group comprising O, S and N;

wherein G_1 and G_3 are C_{1-4} alkyl chains;

10 wherein G_5 is a C_{0-4} alkyl chain;

wherein G_2 is selected from the group comprising:



15 wherein A_3 and A_4 are individually selected from the
group comprising O, N, or S, and G_8 is a C_{1-4} alkyl
chain;

wherein G_4 is a C_{5-8} aryl, a C_{5-8} arylsulfonylamino, an
 C_{5-8} arylamino; and

20 wherein G_6 and G_7 are individually selected from the
group comprising H, F, Cl, I, Br and a C_{1-4} alkyl.

2. The compound of claim 1, wherein X is S.

25 3. The compound of claim 1, wherein X is O.

4. The compound of claim 1, wherein A_1 is N.


5. The compound of claim 1, wherein A_1 is O.

6. The compound of claim 1, wherein A₂ is N.
7. The compound of claim 1, wherein A₂ is O.
- 5 8. The compound of claim 1, wherein G₁ is a C₁ alkyl.
9. The compound of claim 1, wherein G₁ is -(CH₂)₀-.
10. The compound of claim 1, wherein G₁ is a C₂ alkyl.
- 10 11. The compound of claim 1, wherein G₁ is a C₃ alkyl.
12. The compound of claim 1, wherein G₃ is a C₁ alkyl.
- 15 13. The compound of claim 1, wherein G₃ is a C₂ alkyl.
14. The compound of claim 1, wherein G₅ is a C₁ alkyl.
15. The compound of claim 1, wherein G₅ is a C₂ alkyl.
- 20 16. The compound of claim 1, wherein G₂ is represented by the formula:



wherein A₃ is selected from the group comprising O, S and N and A₄ is N.

- 30 17. The compound of claim 1, wherein G₂ is represented by the formula:



35 wherein A₃ and A₄ are individually selected from the group comprising N or O and G₈ is a C₂₋₃ alkyl chain.

18. The compound of claim 1, wherein -N-G₂ forms a guanidino containing moiety.

5 19. The compound of claim 1, wherein -N-G₂ forms a urea containing moiety.

20. The compound of claim 1, wherein -N-G₂ forms a cyclic guanidino containing moiety.

10 21. The compound of claim 1, wherein -N-G₂ forms a cyclic urea containing moiety.

15 22. The compound of claim 1, wherein G₄ is phenylsulfonylamino.


23. The compound of claim 1, wherein G₄ is phenyl.

20 24. The compound of claim 1, wherein G₆ and G₇ are halogens.

25. The compound of claim 1, wherein G₆ and G₇ are the same.

25 26. The compound of claim 1, wherein G₆ or G₇ are F.

27. The compound of claim 1 further represented by the formula:




30 wherein X is selected from the group comprising O and S;

A_1 and A_2 are individually selected from the group comprising O, S and N;

G_1 and G_3 are C_{1-4} alkyl chains;

G_2 is selected from the group comprising:

5



wherein A_3 and A_4 are individually selected from the group comprising O, N, or S, and G_8 is a C_{1-4} alkyl chain;

10 wherein G_4 is a C_{5-8} aryl, a C_{5-8} arylsulfonylamino, or a C_{5-8} arylamino; and

wherein G_6 and G_7 are individually selected from the group comprising H, F, Cl, I, Br and a C_{1-4} alkyl.

15

28. The compound of claim 26, wherein X is S.

29. The compound of claim 26, wherein X is O.

20 30. The compound of claim 26, wherein G_1 is a C_1 alkyl.

31. The compound of claim 26, wherein G_1 is a C_2 alkyl.


32. The compound of claim 26, wherein G_3 is a C_1 alkyl.

25

33. The compound of claim 26, wherein G_3 is a C_2 alkyl.

34. The compound of claim 26, wherein G_2 is represented by the formula:

30



35 wherein A_3 is selected from the group comprising O, S and N and A_4 is N.

35. The compound of claim 26, wherein G_2 is represented by the formula:



wherein A_3 and A_4 are individually selected from the group comprising N or O and G_8 is a C_{2-3} alkyl chain.

10 36. The compound of claim 26, wherein $-N-G_2$ forms a guanidino containing moiety.

37. The compound of claim 26, wherein $-N-G_2$ forms a urea containing moiety.

15 38. The compound of claim 26, wherein $-N-G_2$ forms is a cyclic guanidino containing moiety.

20 39. The compound of claim 26, wherein $-N-G_2$ forms a cyclic urea containing moiety.

40. The compound of claim 26, wherein G_4 is phenylsulfonylamino.

25 41. The compound of claim 26, wherein G_4 is phenyl.

42. A method of treating cancer comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

30 43. A method of treating a tumor comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

44. A method of treating a solid tumor comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.
- 5 45. A method of treating metastasis comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.
- 10 46. A method of inhibiting angiogenesis comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.
- 15 47. A method of inhibiting fibronectin binding comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.
- 20 48. A method of inhibiting osteopontin binding comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.
- 25 49. A method of treating foot and mouth disease comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.
50. A method of treating osteoporosis comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.
- 30 51. A method of treating restenosis comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.
- 35 52. A method of treating ocular diseases comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

53. A method of treating heart diseases comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

5 54. A method of treating arthritis comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

10 55. A method of treating diseases in which abnormal neovascularization occurs comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

15 56. A method of inhibiting $\alpha_v\beta_1$ integrins comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

20 57. A method of inhibiting $\alpha_v\beta_3$ integrin comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

25 58. A pharmaceutical composition for treating cancer comprising a pharmaceutically effective amount of a compound of claim 1.

59. A pharmaceutical composition for treating tumor comprising a pharmaceutically effective amount of a compound of claim 1.

30 60. A pharmaceutical composition for treating solid tumor comprising a pharmaceutically effective amount of a compound of claim 1.

35 61. A pharmaceutical composition for treating metastasis comprising a pharmaceutically effective amount of a compound of claim 1.

62. A pharmaceutical composition for inhibiting angiogenesis comprising a pharmaceutically effective amount of a compound of claim 1.
- 5 63. A pharmaceutical composition for inhibiting fibronectin binding comprising a pharmaceutically effective amount of a compound of claim 1.
- 10 64. A pharmaceutical composition for inhibiting osteopontin binding comprising a pharmaceutically effective amount of a compound of claim 1.
- 15 65. A pharmaceutical composition for treating foot and mouth disease comprising a pharmaceutically effective amount of a compound of claim 1.
- 20 66. A pharmaceutical composition for treating osteoporosis comprising a pharmaceutically effective amount of a compound of claim 1.
- 25 67. A pharmaceutical composition for treating restenosis comprising a pharmaceutically effective amount of a compound of claim 1.
- 30 68. A pharmaceutical composition for treating ocular diseases comprising a pharmaceutically effective amount of a compound of claim 1.
- 35 69. A pharmaceutical composition for treating heart diseases comprising a pharmaceutically effective amount of a compound of claim 1.
70. A pharmaceutical composition for treating arthritis comprising a pharmaceutically effective amount of a compound of claim 1.

71. A pharmaceutical composition for treating diseases in which abnormal neovascularization occurs comprising a pharmaceutically effective amount of a compound of claim 1.

5

72. A pharmaceutical composition for inhibiting α_v integrins comprising a pharmaceutically effective amount of a compound of claim 1.

10

73. A pharmaceutical composition for inhibiting $\alpha_v\beta_3$ integrin comprising a pharmaceutically effective amount of a compound of claim 1.

15

74. A combination useful for the treatment of cancer comprising at least one compound of claim 1 with at least one other anticancer agent or antiangiogenic agent.

20

75. A combination useful for the treatment of cancer comprising at least one compound of claim 1 with at least one other anticancer agent selected from the group consisting of alkylating agents, antitumor antibiotics, antimetabolites, biological agents, hormonal agents, nitrogen mustard derivatives and plant alkaloids.

25